Last reviewed · How we verify
NCT03931655
Photoacoustic Lymph Node Imaging
trial testing Spectroscopic photoacoustic imaging in Breast Cancer in 1 participant. Terminated before completion.
2 November 2023
Quick facts
| Lead sponsor | Geoff Luke |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 1 |
| Start date | 1 November 2019 |
| Primary completion | 2 November 2023 |
| Estimated completion | 2 November 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Spectroscopic photoacoustic imaging
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Geoff Luke
Who can join
18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this spectroscopic photoacoustic imaging study, the investigators will acquire images (only) to: 1. determine if spectroscopic photoacoustic imaging can acquire high fidelity images in a clinical setting, 2. discover if blood oxygen saturation changes are observable in breast cancer patients during early stages of metastatic invasion, and 3. compare the sensitivity and specificity of photoacoustic imaging with ultrasound imaging for the detection of lymph node metastases. The results from imaging will not be used in any decision making process. This study is solely used to test the photoacoustic imaging device and evaluate it against the current standard of care. The device is completely noninvasive and uses only safe levels of energy as determined by the American National Standards Institute (ANSI) and the FDA. The device does not pose a serious to the health, safety, or welfare of the patient.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Image-guided tumor surgery: The emerging role of nanotechnology.
Wojtynek NE, Mohs AM. · · 2020 · cited 34× · PMID 32162485 · DOI 10.1002/wnan.1624
Verify or expand the search:
- PubMed search for NCT03931655
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03931655 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Geoff Luke
- Last refreshed: 7 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03931655.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing